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Abstract 
Objective: To clarify how the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) concept of certainty of evidence applies to certainty ratings of test accuracy. 
Study Design and Setting: After initial brainstorming with GRADE Working Group members, we 
iteratively refined and clarified the approaches for defining ranges when assessing the certainty of 
evidence for test accuracy within a systematic review, health technology assessment, or guidelines.  
 
Results: Ranges can be defined both for single test accuracy and for comparative accuracy of multiple 
tests. For systematics reviews and health technology assessments, approaches for defining ranges 
include some that do not require value judgments regarding downstream health outcomes. Key 
challenges arise in the context of a guideline that requires ranges for sensitivity and specificity that 
are set considering possible effects on all critical outcomes. We illustrate possible approaches and 
provide an example from a systematic review of a direct comparison between two test strategies. 
Conclusions: This GRADE concept paper provides a framework for assessing, presenting, and making 
decisions based on the certainty of evidence for test accuracy. More empirical research is needed to 
support future GRADE guidance on how to best operationalize the candidate approaches. 
 
Keywords: Certainty of evidence, test accuracy, GRADE, Guidelines, Systematic reviews, Health 
technology assessments 
 
Running title: Defining ranges for certainty ratings of diagnostic accuracy 
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Introduction 
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) concept of 
certainty of evidence (also called quality of evidence) represents our confidence that the true effect 
lies above or below a threshold, or in a specified range (1). To assess the certainty of evidence for an 
individual outcome, authors of systematic reviews, health technology assessments or guidelines 
need to specify the thresholds or ranges they are using and the associated rationale. Several 
approaches exist for setting thresholds and ranges. For recommendations in clinical practice and 
public health guidelines, GRADE has suggested setting a threshold based on consideration of all 
critical outcomes. For systematic review authors, we have illustrated three different approaches: 
expressing certainty in the range set by the 95% confidence interval (CI), certainty in the direction of 
effect, or certainty in a particular magnitude of effect, e.g. small, medium or large.  
 
Although GRADE has illustrated the concept of certainty using effects of treatment interventions, the 
guidance to specify ranges or thresholds also applies to questions of diagnostic tests. When 
diagnostic intervention studies comparing alternative diagnostic test strategies with direct 
assessment of patient-important outcomes are available (such as RCTs addressing the impact on 
survival after a screening strategy), the approaches for setting thresholds or ranges previously 
presented apply (1). In this paper, we will explore the concepts when there are no such studies. 
 
If no studies have directly compared the effects of alternative test strategies on downstream health 
outcomes, modeling the impact of diagnostic accuracy on the health outcomes could inform 
management decisions (2, 3). For example, false negatives (FN) and false positive (FP) test results, by 
missing or delaying the diagnosis (FN) or through unnecessary treatment (FP), can adversely impact 
health outcomes (2, 3). GRADE previously described that to evaluate impact, one may, through 
formal or informal modeling, link different types of evidence: diagnostic test accuracy estimates (e.g. 
sensitivity and specificity), direct effects of the test(s) (e.g. complications of an invasive test), natural 
course of the condition, treatment effectiveness and the link between the test results and clinical 
management (2-5).  Arriving at an overall rating of certainty of evidence requires rating every 
component.  
 
This article explores possible ways of setting thresholds or ranges for rating certainty in diagnostic 
test accuracy, and what this would mean in the context of systematic reviews, health technology 
assessment and healthcare recommendations. GRADE has described approaches for setting 
thresholds or ranges in terms of levels of contextualization (1). Box 1 presents levels of 
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contextualization for diagnostic accuracy, concepts that this paper will further illustrate. The 
discussion is consistent with previous guidance on rating certainty in diagnostic accuracy (2-5). 
 
Box 1. Degree of contextualization when defining range 
Non-contextualized (primarily for systematic reviews and health 
technology assessments).  The ranges used are independent of value 
judgments regarding – e.g. the relative importance of false negatives 
versus false positives.  
Partially contextualized (primarily for systematic reviews and health 
technology assessments). The ranges depend on some value 
judgment –  e.g. the importance of downstream health consequences 
of true and false positives and negatives. This approach to 
contextualization requires setting boundaries of ranges expressed in 
absolute terms for a given prevalence. 
Fully contextualized (primarily for guidelines and other decision 
making). The boundaries are set considering the range of possible 
effects on all critical outcomes, bearing in mind the decision(s) that 
need to be made, and the associated values and preferences. This 
approach to contextualization requires setting boundaries of ranges 
expressed in absolute terms for a given prevalence. 
 
 
Definitions and scope 
In our previous work clarifying the construct of certainty of evidence, we used the term threshold as 
a set border (e.g. a threshold at which the benefits start outweighing the harms) and the term range 
when using two borders (e.g. the upper and lower limits of a small effect). Although one could use 
the same terminology for the borders set in test accuracy, to avoid confusion with the thresholds 
used to dichotomize the test results for a particular test, throughout this paper we will use range 
meaning threshold or range. 
 
We use the term test strategy to denote a combination of tests (e.g. clinical test followed by MRI), 
not to be confused with test-treatment strategy that also includes the treatment that is guided by 
the test result (2). The test under consideration can have different roles within a test strategy: to 
replace an existing test, as triage test before an existing test, as an add-on to an existing test (6), or 
parallel to an existing test (7). When evaluating diagnostic accuracy of a test, it is important to define 
the role of the test to address the accuracy of the full test strategy. The approaches for setting ranges 
suggested in this paper apply to all types of test strategies. We will present the approaches for 
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comparisons between tests as well as for single tests, but our main focus will be on the comparative 
scenario which we will further explain below. 
 
When addressing the certainty of evidence for test accuracy, we are presenting and rating ranges for 
sensitivity and specificity. However, when interpreting a test result in clinical practice, multilevel 
likelihood ratios or multivariable approaches may be more useful.   
 
We refer to non-contextualized certainty ratings if authors make choices of ranges without value 
judgments, that do not involve modelling. The term fully contextualized refers to situations in which 
the entire health care question/context is considered when assessing the certainty of sensitivity and 
specificity, typically in the setting of a guideline (1). Less contextualized ratings are typically made in 
systematic reviews and health technology assessments (HTA). We will continue to make distinctions 
between certainty ratings that are fully contextualized (considering all critical outcomes with their 
associated values within a particular decisional context), partly contextualized (including some value 
judgment regarding the importance of the individual outcome), and non-contextualized (without 
value judgments). Non- or partially contextualized approaches refer only to the chosen ranges, and 
not to other decisions. For instance, authors of systematic reviews always need to consider the 
context of interest, for example in their eligibility criteria (e.g. only including studies with a certain 
prevalence or setting), or when assessing indirectness. 
 
Currently, authors use decision models of varying complexity to inform decisions regarding test 
strategies: ranging from back of the envelope estimations of the possible consequences to advanced 
models estimating all benefits and harms to the patients as well as the uncertainty associated with 
the parameters in the model (3).  We will exemplify the contextualized approaches using a simple 
model estimating the consequences of changes in the sensitivity and specificity of the test strategies. 
However, the concepts we present apply to any level of modelling, requiring only consideration of all 
critical direct and downstream outcomes.  
 
Comparisons of test strategies  
If the goal is to evaluate two test strategies, one can compare the accuracy of the two tests using a 
study design in which one administers the tests in the same population comparing to the same 
reference standard (direct comparison) (8). In many cases, however, primary research has only 
studied the accuracy of single tests against a reference standard in separate populations and 
separate studies. In these cases, the comparison between the relevant tests will be indirect, leading 
to additional challenges beyond the scope of this paper. 
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Table 1 shows possible approaches for setting ranges in sensitivity and specificity and illustrates what 
the certainty ratings represent for a direct comparison versus a single test. We will start by 
presenting an overview of the suggested approaches and then continue with an example of applying 
the approaches to a direct comparison. 
 
Non-contextualized ratings of test accuracy (typically for systematic reviews and health technology 
assessments) 
We refer to the first two approaches presented in Table 1 as non-contextualized, meaning that the 
choice of the boundaries for the range of sensitivity and specificity does not involve value judgments 
(box 1). That is, the importance of the number of false negatives or false positives does not bear on 
the ranges chosen, and the downstream consequences of the test results have no influence on the 
certainty ratings of sensitivity and specificity.  Analysts use these approaches when they wish to 
assess the certainty of the test accuracy without further interpreting the results or providing advice.  
 
Using the ranges of the confidence intervals 
The first approach assesses how certain we are that the true sensitivity and specificity lies within the 
observed confidence intervals. Using this approach, one omits the rating of imprecision, i.e. one 
could have high certainty that the true sensitivity or specificity lies within the range set by the 
confidence interval regardless of whether this range is wide or narrow. The ranges can be presented 
for sensitivity and specificity, or for the number of false positives and false negatives given a 
particular pre-test probability.  In comparing two tests, one will rate the certainty of the difference in 
sensitivity and specificity, or false positives and negatives between the tests under consideration. 
This approach could potentially mean that we express high certainty in very imprecise results.  
 
Using the direction of effect 
The second approach assesses our certainty regarding whether a difference exists between the 
accuracy of two test strategies. In other words: How certain are we that Test A has a higher/lower 
sensitivity or specificity than Test B? In some cases, one would want to address the certainty that the 
true difference in test accuracy lies close to no difference. This requires a decision regarding what 
difference would be trivial and thus requires a partly contextualized judgment that we describe 
below.  
 
Partly contextualized ratings of certainty: Ranges of magnitude of accuracy (typically for systematic 
reviews and health technology assessments) 
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The third option described in Table 1 is to rate our certainty in a specific accuracy. When applying 
this approach to a comparison between two tests, one could specify categories of no or trivial, small, 
moderate, or large difference in accuracy. Similarly, when evaluating the accuracy of a single test in 
comparison to the reference standard, one could specify trivial, low, moderate, or high accuracy. This 
approach requires setting boundaries of ranges expressed in absolute terms for a given prevalence – 
boundaries that likely will depend on the value placed on the direct effects (i.e. burdens/adverse 
effects) of the test as well as the downstream health consequences of the true and false positives 
and negatives.  
 
For example, consider a situation in which the downstream health consequences of a management 
decision are serious, such as recurrence of disease.  In such situations, ranges of false positives and 
negatives will have a lower value than if the downstream consequences are less serious such as 
minor adverse events or length of hospital stay.   
 
Fully contextualized ratings (typically for guidelines) of test accuracy 
When we make fully contextualized ratings, we are simultaneously weighing the benefits and harms 
of every critical or important health outcome or even all desirable and undesirable consequences (1) 
(box 1). In the absence of studies comparing the health consequences of tests, one would ideally use 
a fully developed model for assessing the effects of the test strategies on patient important 
outcomes. If such models can generate estimated effects with confidence intervals, one can make 
fully contextualized ratings of the patient important outcomes in the same way as we have 
previously described (1). The accuracy data would in this case be one of several pieces of data 
feeding into the model.  
 
Currently guideline panels seldom have access to advanced models.  As a result they will inevitably  
focus on diagnostic accuracy (9-11). Here we discuss how one can, in these cases, make fully 
contextualized ratings of sensitivity and specificity, i.e. address whether one would make a different 
decision at either end of the certainty ranges.  One can then use models or explicit considerations to 
decide what sensitivity and specificity one would require to recommend a particular test.  That is, 
what levels of sensitivity and specificity would be required to ensure that the desirable health effects 
will outweigh the undesirable. In some cases, it is also possible to set ranges for sensitivity and 
specificity by inferring decision thresholds from other recommendations and decisions about testing 
(12). 
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When all else is judged exactly equal between the two test strategies (e.g. side effects, invasiveness, 
resources considerations, timing of test, location of test in the care pathway, feasibility, availability), 
the fully contextualized range would be the same as the non-contextual no-effect range.  Although it 
is unlikely to occur, one could then base a decision solely on knowledge of whether the test accuracy 
increases or decreases with one test-strategy compared with another (9, 13, 14).  
 
Fully contextualized ranges are often decided on through discussions in guideline panels, based on 
what is known about the direct and downstream health outcomes of the test strategies. In some 
cases, panels conduct formal surveys of their members to establish test and treatment thresholds 
(15). In some situations, considering downstream health outcomes can be sufficient and no formal 
modeling is needed - for example if it is obvious that the health consequences of using the test would 
be negative.  
 
We will now illustrate how simple models of health outcomes can inform the choice of fully 
contextualized ranges for sensitivity and specificity.  If the values are very uncertain, or the results 
will be used in several different contexts, one can provide several certainty ratings, each for a specific 
set of values. 
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Table 1. Possible ways of setting ranges for sensitivity and specificity, and what the certainty expressed will 
represent for a comparison between tests vs single test 
Degree of 
contextualization 
Range How it is set What the certainty rating represents 
For a comparison 
between tests 
For a single test 
 
Non-
contextualized 
 
(primarily for 
systematic reviews 
and health 
technology 
assessment) 
Range: 95% 
Confidence 
Interval 
 
Using existing limits of 
the 95% CIs, which 
implies precision is 
not routinely part of 
the rating 
Certainty that the true 
difference in accuracy lies 
within the confidence 
region of the tests 
compared or the true 
difference in sensitivity 
and specificity lies within 
their respective 
confidence intervals 
 
Certainty that the true 
sensitivity and specificity 
lies within their respective 
confidence intervals 
Difference ≠ 0 Using the threshold of 
null effect 
Certainty that the 
sensitivity or specificity of 
one test strategy differs 
from that of another 
Not applicable 
 
Partially 
contextualized 
 
(primarily for 
systematic reviews 
and health 
technology 
assessment) 
 
Specified 
magnitude  
(set in natural 
frequencies for 
a given 
prevalence) 
E.g. a small difference 
in sensitivity or 
specificity can be 
defined as a 
difference small 
enough that one 
might consider not 
using the test if 
adverse effects or 
costs are appreciable  
Certainty in a specified 
magnitude of difference 
between the sensitivity or 
specificity of two tests 
(e.g. no or trivial, small, 
medium or large 
difference) 
Certainty in a specified 
magnitude of sensitivity 
or specificity (e.g. low, 
moderate or high 
accuracy)* 
Fully 
contextualized 
 
(primarily for 
guidelines) 
Threshold 
determined 
with 
considerations 
of all critical 
outcomes 
(set in natural 
Considering the range 
of possible effects on 
all critical outcomes 
(3), bearing in mind 
the decision(s) that 
need to be made, and 
the associated values 
For each outcome (in this 
case sensitivity and 
specificity), ratings 
represent our confidence  
that the overall balance 
between net benefit and 
net harm will not differ 
For each outcome (in this 
case sensitivity and 
specificity), ratings 
represent our confidence 
that the overall balance 
between net benefit and 
net harm will not differ 
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frequencies for 
a given 
prevalence) 
 
and preferences from one end of the 
certainty range** to the 
other. 
 
from one end of the 
certainty range** to the 
other.  
*This will have to be specific to the test, condition and setting. Sensitivity of 97% may be considered 
extremely accurate for some conditions/test/setting while it may be considered low accuracy for a 
different scenario. This decision will be informed by the patient and population consequences based 
on the test results. 
**By certainty range we mean the range in which we anticipate that the true sensitivity or specificity  
may lie, after considering not only precision, but also risk of bias, inconsistency, indirectness and 
publication bias (1, 16). 
 
 
Applying ranges to direct comparisons of accuracy between test strategies 
To make decisions about tests direct comparisons of the relevant test strategies are ideal. We will 
show what the approaches for setting ranges would mean in such a setting using the direct 
comparison of accuracy between two tests for cervical cancer screening, the Human Papilloma Virus 
(HPV) test (HPV DNA-PCR testing) and unaided visual inspection of the cervix with acetic acid (VIA) 
(17). 
 
Cervical intraepithelial neoplasia (CIN) is a premalignant lesion diagnosed by histology, in 3 stages: 
CIN 1, CIN 2, and CIN 3.  If left untreated, CIN 2 or 3 (CIN2-3) can progress to cervical cancer. HPV 
causes virtually all cancer of the cervix and is the most common sexually transmitted disease (18). 
The setting for this example is a screen-treat strategy in low- and middle-income countries, in which 
treatment is provided to all with a positive screening test.  
 
We used this example in prior GRADE articles (2, 3, 5). It is based on a systematic review of five 
studies assessing the accuracy of HPV and VIA against a common reference standard (a combination 
colposcopy with or without biopsy and in some instances clinical follow up as well) (17). For the HPV 
test, the pooled sensitivity was 95% (95% CI: 84 to 98) and the pooled specificity 84% (95% CI: 72 to 
91), and for VIA the pooled sensitivity was 69% (95% CI: 54 to 81) and the pooled specificity 87% 
(95% CI: 79 to 92). The diagnostic sensitivity is 26% points higher with HPV compared to VIA (95% CI: 
11-41% higher) while the specificity is 3% lower (95% CI: 15% lower to 8% higher) (method in 
appendix 1). At the estimated prevalence in the general population of 2%, based on WHO data (18), 
if 1000 women are screened with the HPV test instead of VIA, 5 more true positives will be found (2 
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to 8 more) while there will be 34 more false positives (147 more to 78 fewer), who would receive 
treatment. 
 
No serious concerns regarding risk of bias, indirectness or publication bias for this comparison of test 
accuracy were identified. Whether there are serious problems with inconsistency (the estimated 
differences in sensitivity with HPV vs VIA in the included five studies ranged from an increase of 1% 
to an increase in 56%, and the estimated difference in specificity ranged from a decrease of 22% to 
an increase in 9%) and imprecision will depend on the ranges used; those judgments are described 
below. 
 
Non-contextualized approaches (primarily for systematic reviews or health technology assessments) 
Using the ranges of the confidence intervals 
The first non-contextualized approach listed in Table 1 is to assess our certainty in the ranges defined 
by the 95% confidence intervals. In this case we would be rating how certain we are that the 
sensitivity of the HPV test is 11% to 41% higher than VIA and the specificity is somewhere between 
15% lower to 8% higher. Since the estimated difference of the test accuracy results in individual 
studies are outside of these ranges, we might rate down for inconsistency in both sensitivity and 
specificity. With this approach, we do not judge the width of the intervals, i.e. precision is omitted 
from the ratings, and since no serious concerns were identified for the other domains, we would end 
up with moderate ratings of certainty for the ranges set by the 95% CIs (Table 2). Different target 
audiences can use these ranges with certainty ratings for their particular goals, for example as input 
into a model for estimating downstream consequences. 
 
Using the direction of effect 
The second non-contextualized approach for defining ranges is to use the boundary of no difference 
in sensitivity or specificity. When doing so, we are addressing our certainty in the direction (increase 
or decrease) of sensitivity and specificity, neglecting the magnitude of the difference. In this case, we 
would be rating how certain we are that by using the HPV test rather than VIA we would increase the 
sensitivity and decrease the specificity. Since the entire confidence interval for the difference in 
sensitivity lies on one side of no effect, as well as the estimated differences in all the included 
studies, we would not rate down for imprecision or inconsistency and we would have high certainty 
that the HPV test indeed increases the sensitivity for detecting CIN 2-3.  On the other hand, there is a 
serious problem with imprecision for specificity since the confidence interval reaches from a 
decrease of 15% to an increase of 8%. Furthermore, individual studies have estimated differences in 
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specificity between an increase in 9% and a decrease in 22%, and we would therefore rate down for 
both imprecision and inconsistency (Table 2).  
 
Partly contextualized ratings of certainty: Ranges of magnitude of accuracy (primarily for systematic 
reviews and health technology assessments) 
Using this approach, one would define ranges for a trivial, small, moderate or large difference in 
sensitivity and specificity. Since these judgments are based on the downstream health consequences, 
reviewers must address these clearly in the beginning of the review process. In our example, a simple 
model was used based on five outcomes: cervical cancer, cervical cancer related mortality, major 
bleeds, premature delivery and major infections (Figure 1, and detailed explanation in appendix 1). 
Cervical cancer and cervical cancer related mortality due to false negative test results could be 
reduced using a test with a higher sensitivity. Major bleeds, premature delivery and major infections 
due to false positive test results can be reduced using a test with a higher specificity.  
 
 
 
Figure 1. Estimated consequences of the four possible test results for CIN. The setting for this 
example is a screen-treat strategy in low- and middle-income countries, in which treatment is 
provided to all with a positive screening test. 
 
The model provides approximations regarding how differences in sensitivity and specificity will affect 
the outcomes of interest. At a prevalence of 2% (18), increasing sensitivity by 1% would result in 
approximately 2 fewer cervical cancer related deaths and 3 fewer cases of cervical cancer per million 
women screened. A 1% increase in specificity will result in approximately 3 fewer major bleeds, 6 
fewer premature births and 1 less major infection per million women screened. One can use this 
information to guide the choice of ranges for no or trivial, small, moderate, or large difference in 
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sensitivity or specificity. As previously noted, the choices of ranges will likely differ depending on the 
value placed on the outcomes. In contrast to a range set directly on a patient-important outcome, 
the ranges for sensitivity and specificity can be affected by several downstream health outcomes. 
This is illustrated in Table 3, in which examples of ranges for the difference in sensitivity and 
specificity for HPV versus VIA are presented.  
 
For this example, the point estimate for sensitivity was within the presented range of a large 
increase. As the CI crosses the border of a moderate increase, and individual studies have estimated 
differences that can be considered trivial or small, the certainty rating is low due to imprecision and 
inconsistency. For specificity, the point estimate is within the range defined as a no or trivial 
difference. Since the CI crosses the border to a small decrease, one would rate down for imprecision. 
Also, one of the included studies has an estimated decrease of 22% in specificity (considered a 
medium-large difference), which might warrant rating down for inconsistency, in which case the 
certainty rating would be low (Table 2). 
 
Table 2. Examples of certainty ratings for the difference in sensitivity and specificity between HPV 
and VIA. The partially and fully contextualized ranges are set considering a prevalence of 2%. 
Approaches Examples of set ranges Certainty 
 
Range: 95% Confidence 
Interval 
 
Sensitivity: The 95% CI, in this 
case an increase by 11-41% 
(at a pre-test probability of 
2%, 2-8 more true positives 
per 1000 women screened.) 
 
Specificity: The 95% CI, in this 
case a decrease by 15% to 
increase by 8% (at a pre-test 
probability of 2%, 147 more 
to 78 fewer false positives per 
1000 women screened) 
 
We have moderate certainty that the 
true increase in sensitivity is between 11 
and 41% (rating down for inconsistency)  
 
 
We have moderate certainty that the 
true difference in specificity is between 
an 15 % decrease to an 8% increase 
(rating down for inconsistency) 
rsens ≠ 1, rspec ≠ 1 
 
Direction of effect 
 
We have high certainty that the 
sensitivity of HPV testing is higher than 
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 VIA for detecting CIN 2-3  
 
We have low certainty that the 
specificity of HPV testing is lower than 
VIA for detecting CIN 2-3 compared to 
VIA (rating down for imprecision and 
inconsistency) 
Specified magnitude of 
difference in sensitivity 
and specificity 
 
The set range for a large 
effect on sensitivity was a 
difference in more than 4 TP 
per 1000 screened 
(corresponds to mortality of 
more than 50 and cervical 
cancer cases of more than 60, 
per million screened) 
 
The set range for a no or 
trivial effect on specificity 
was a difference in up to 200 
FP per 1000 screened 
(corresponds to a difference 
of up to approx.33 major 
bleeds, 120 premature births, 
13 major infections per 
million women screened) 
 
We have low certainty that HPV has a 
large increase in sensitivity compared to 
VIA (rating down for imprecision and 
inconsistency) 
 
 
 
 
 
We have low certainty that there is no 
or trivial difference in specificity 
between HPV and VIA (rating down for 
imprecision and inconsistency) 
Range determined with 
considerations of all 
critical direct and 
downstream health 
outcomes or all 
desirable and 
undesirable 
consequences 
Thresholds based on the 
values we place on mortality 
and cervical cancer vs major 
bleeds, premature delivery 
and major infections.  
Considering downstream health 
outcomes, we have low certainty in the 
sensitivity outcome, i.e. this outcome 
may not shift the overall balance 
between net benefit and net harm 
(rating down for imprecision and 
inconsistency). 
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 Considering downstream health 
outcomes, we have low certainty in the 
specificity outcome, i.e. this outcome 
may not shift the overall balance 
between net benefit and net harm 
(rating down for imprecision and 
inconsistency). 
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Table 3. Example of ranges set for different magnitudes of difference in sensitivity and specificity for 
HPV vs VIA*. The boundaries of the ranges represent a hypothetical group consensus based on the 
importance placed on cervical cancer and cervical cancer related mortality (for sensitivity), and major 
bleeds, premature births and major infections (for specificity). 
Sensitivity Specificity 
No or trivial difference in sensitivity: 0-4% 
Difference in 0-1 TP found per 1000 screened 
(corresponds to a difference in mortality of up 
to 10, and cervical cancer cases of up to 12, per 
million screened) 
No or trivial difference in specificity: 0-10% 
Difference in 0-100 FP per 1000 screened 
(corresponds to a difference of up to approx.33 
major bleeds, 60 premature births, 13 major 
infections per million women screened) 
Small difference in sensitivity: 4-10% 
1-2 TP per 1000 screened 
(corresponds to a difference in mortality of 
around 10-25, and cervical cancer cases of 
around 12-30, per million screened) 
 
Small difference in specificity: 10-20% 
100-200 FP per 1000 screened 
(corresponds to a difference of approx.33-66 
major bleeds, 60-120 premature births, 13-26 
major infections per million women screened) 
Moderate difference in sensitivity: 10-20% 
2-4 TP per 1000 screened 
(corresponds to a difference in mortality of 
around 25-50, and cervical cancer cases of 
around 30-60, per million screened) 
Moderate difference in specificity: 20-30% 
200-300 FP per 1000 screened 
(corresponds to a difference of approx.66-100 
major bleeds, 120-180 premature births, 26-39 
major infections per million women screened) 
 
Large difference in sensitivity: more than 20% 
›4 TP per 1000 screened 
(corresponds to mortality of more than 50 and 
cervical cancer cases of more than 60, per 
million screened) 
Large difference in specificity: more than 30% 
›400 FP per 1000 screened 
(corresponds to a difference of approx. 100 or 
more major bleeds, 240 or more premature 
births, 39 or more major infections per million 
women screened) 
 
*  The values for sensitivity and specificity represent the absolute ranges at a prevalence of 2%  
 
Fully contextualized ratings (primarily for guidelines or other decisions) of test accuracy 
When making fully contextualized ratings of the difference in sensitivity and specificity, we start by 
considering the downstream health outcomes (Figure 1). Moreover, just as for treatment 
interventions, we will have to specify values for all critical health outcomes. The values should be 
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those of the patients, and the process for obtaining them can include a systematic review of the 
relevant literature, the experience of the topic experts in conducting shared decision-making, 
consultation with patients and patient groups, and conduct of targeted surveys (19-21). 
 
In the present example, the guideline panel might infer that women eligible for screening would 
value major infections and major bleeds equally, premature delivery twice as high, and would place 
an appreciably greater value on cervical cancer and cervical cancer related mortality, say seven and 
20 times higher, respectively. Such an inference may be informed by, for example, reported utility 
estimates from similar clinical contexts (22-24). 
 
The question will be how much harm we are willing to accept given a certain benefit, or the other 
way around. For this particular example, the guideline panel will consider how certain they are that 
the increase in sensitivity is high enough to outweigh the potential decrease in specificity. At a 
prevalence of 2%, the estimated effect of increasing sensitivity with 1% is 2.5 fewer cervical cancer 
related deaths and 3 fewer cervical cancer cases per million women screened. Correspondingly, the 
estimated effect of increasing specificity with 1% would be 6 fewer premature deliveries, 1.3 fewer 
major infections and 3.3 fewer major bleeds per million women screened.  
 
Using the estimated effects on downstream health outcomes and the values suggested above, the 
guideline development group decided to accept a 4.5% decrease in specificity for every percentage 
increase in sensitivity (calculation in Appendix Table 1). This means that even if the lower limit of the 
CI of sensitivity (11% increase) were true, we would accept an increase in specificity of 50%. Since the 
entire CI of specificity is within this range, one would not rate down for imprecision in the specificity 
outcome. For the same reason, we would not rate down for imprecision in the sensitivity outcome. 
One should, however, also consider the uncertainty of the estimated downstream health outcomes 
on which we are basing the chosen range. Is it, for example, possible that the increased risk of 
premature delivery in treated women is 0.4% instead of the estimated 0.06%? If this is plausible, we 
would only accept an increase in specificity of 0.9% for every percentage increase in sensitivity 
(calculation in Appendix Table 2), and rating down for both imprecision and inconsistency for 
sensitivity and specificity would be warranted. 
 
Just as for intervention effects, the fully contextualized ratings represent a sensitivity analysis 
addressing whether the test outcomes being considered (in this case sensitivity and specificity) are 
influential in altering the overall net benefit or harm. 
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Certainty ratings in the Evidence to Decision framework (EtD) 
As illustrated above, the ranges with different levels of contextualization will take into account one 
or several of the criteria in the EtD (figure 2, (2)). For the non-contextualized ranges, only test 
accuracy is considered, whereas some level of consideration of the positive and negative health 
outcomes and values of these will be needed to set the partially contextualized ranges. For the fully 
contextualized ranges, all direct and downstream health outcomes are considered, as well as the 
balance of effects based on patient values. Depending on the perspective taken in the guideline one 
could choose to also incorporate resource use, as well as issues of equity, acceptability and feasibility 
when setting the fully contextualized ranges for sensitivity and specificity. For example, from a policy 
makers’ perspective, one might want to include resources, such as further expensive testing in false 
positives, or more expensive treatments due to delayed diagnosis in false negatives. 
 
 
 
Figure 2. The 17 items in the Evidence to Decision framework (2) and how the illustrated non-, 
partially-  and fully contextualized approaches for setting ranges relate to them. 
 
DISCUSSION 
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This paper illustrates the concepts of certainty of evidence applied to test accuracy. We show that 
defining ranges for the certainty ratings is important, since the ranges chosen will affect the 
interpretation of the result and the degree of certainty presented.  More empirical data is needed to 
inform approaches for defining ranges that would be most useful, and to what degree different levels 
of modeling will affect the decisions being made.  
 
Situations also exist that are complicated by issues related to research on tests.  For example, 
primary research on test accuracy is historically seldom performed with direct comparisons between 
tests. Therefore, most often systematic review authors, health technology assessors and guideline 
developers will not have access to primary studies directly comparing the accuracy of the relevant 
test strategies. Although this is starting to change, currently many decisions will have to be made 
based on indirect comparisons. Future studies are needed to inform how best to deal with these 
specific challenges.   
 
Modelling of downstream health outcomes will inevitably include assumptions, which some review 
authors might feel reluctant to make. However, making decisions about tests will always require 
judgments regarding the importance of outcomes, though guideline panels or decision-makers may 
not make their judgments explicit.  An advantage of the fully contextualized approach for guideline 
development presented in this paper, is the transparency of all assumptions made.  
 
Conclusions 
Previous work has shown that the certainty of evidence is a rating of our certainty that the true 
effect lies in a particular range. Although the examples related to intervention effects, previous 
guidance suggested that review authors specify the relevant thresholds underlying the certainty 
judgments.  This guidance also applies to questions of diagnosis. In this conceptual paper, we have 
illustrated what the suggested approaches for defining ranges would mean when rating sensitivity 
and specificity in the context of systematic reviews, health technology assessments or guidelines. 
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APPENDIX – background to HPV example, methods and model 
 
Background   
Cervical intraepithelial neoplasia (CIN) is a premalignant lesion that is diagnosed by histology, in 3 
stages: CIN 1, CIN 2, and CIN 3.  If left untreated, CIN 2 or 3 (CIN2-3) can progress to cervical cancer. 
Standard practice for diagnosing CIN is to perform a colposcopy, biopsy suspicious lesions, and then 
treat only when CIN2-3 has been histologically confirmed. Additionally, it is known that persistent 
viral infection with carcinogenic Human Papilloma Virus (HPV) genotypes causes virtually all cancer of 
the cervix. HPV is the most common sexually transmitted disease known. Most HPV infections, 
including carcinogenic HPV genotypes, typically resolve within 6 to 12 months. However, women 
with persistent carcinogenic HPV infections are at risk of developing precancerous lesions, although 
not all persistent infections progress. Treatment is typically surgical and there are three principal 
interventions available in low- and middle-income countries to treat CIN: cryotherapy (freezing the 
lesion), large loop excision (cutting using electrocautery) of the transformation zone (LEEP/LLETZ), 
and cold knife (cutting without electrocautery) conisation (CKC) (1).  
An alternative approach to diagnose and treat CIN is to ‘screen and treat’ in which treatment 
decisions are based on a screening test, instead of histologically confirmation of CIN 2-3, and 
treatment is provided soon, or ideally, immediately after a positive screening test. The goal of a 
screen and treat program for cervical cancer is to reduce cervical cancer and related mortality with 
relatively few adverse events. Common screening tests that are widely used are tests for the Human 
Papillomavirus (HPV), cytology (PAP) and unaided visual inspection with acetic acid (VIA). Countries 
currently providing or considering screen and treat strategies may be uncertain about whether or not 
to provide one test (or strategy) over another. 
For the rest of this example, we will be interested in a screen-treat strategy assessing HPV compared 
to VIA as a screening test for women who are at risk for CIN 2-3 and then followed by cryotherapy as 
the treatment of choice. 
 
METHODS - Summary estimates of sensitivity and specificity 
We used the bivariate random-effects model (2, 3) to estimate the summary sensitivity and 
specificity of both HPV and VIA. This approach allowed us to calculate summary estimates of the 
mean sensitivity and specificity while dealing with potential sources of variation caused by: (1) 
imprecision of sensitivity and specificity estimates within individual studies; (2) correlation between 
sensitivity and specificity across studies; and (3) variation in sensitivity and specificity between 
studies. All five available studies were included in the model twice: once for HPV and once for VIA. A 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 23
covariate for test-type was added to the model, so that we could assess the association between 
test-type and sensitivity or specificity, or both. We included separate variance terms for each test. 
Based on the summary estimates of sensitivity and specificity, we estimated the difference in 
estimated sensitivity and specificity between the two tests. 
 
METHODS – Outcomes of the simple model for HPV vs VIA 
 
Prevalence of CIN 
The overall prevalence of CIN2-3 is estimated to 2% in the general population (4). 
 
Mortality from cervical cancer 
In our simple model, we assumed that mortality from cervical cancer is a consequence of having CIN 
which means that mortality from cervical cancer can happen in any patients who have CIN. However, 
mortality from cervical cancer will happen at a different rate in those who are treated (TP) and in 
those who are missed and not treated (FN). We also assumed that there will be no mortality from 
cervical cancer in those who do not have CIN including both TN and FP. 
To calculate the mortality from cervical cancer, we assumed 250 deaths per 350 women with cervical 
cancer. These numbers are based on Eastern Africa age standardized rates of cervical cancer and 
mortality provided by WHO at http://globocan.iarc.fr) 
 
Mortality is 250/350 in the group with cervical cancer = 0.7142 
 
To calculate cervical cancer incidence in women with persistent CIN 2/3, we assumed 350 cervical 
cancers per 14000 women who have persistent CIN 2/3 (i.e. FN).  This incidence is based on Eastern 
Africa age standardized rate of cervical cancer of 350 cervical cancers per 1000000 women, of whom 
2% have CIN 2/3 (20000 women with CIN 2/3, and a subsequent 30% regression for a total of 14000 
with persistent CIN 2/3).   This data is available from WHO at http://globocan.iarc.fr/). 
Incidence of cervical cancer in woman with persistent CIN2/3 = 350/14000 = 0.025 
 
From the above, we calculated the mortality in women with persistent CIN2/3 as: (0.7142 * 0.025) = 
0.0178 
Our calculations in the model are based on 70% natural persistence of CIN 2/3 with no treatment 
(30% regression) in FN. 
  
(Persistence of CIN2/3 in FN group = (FN*0.7) 
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Mortality in FN group will be (FN*0.7) * 0.0178 
 
We assumed all TP are treated. Based on systematic reviews of treatment, we established that 
persistence/recurrence rates of CIN 2/3 are 5.3% in cryotherapy, and this was the value used in the 
model. 
Mortality in TP group was (TP* 0.053) * 0.0178 
 
In this example, the sensitivity of the test is a major determinant of the effect on mortality. This 
happens because: 
• The outcome evaluated (mortality), depend on progression of CIN 2/3 in patients 
who have it whether treated (TP) or not (FN). 
• Mortality occurs in a different proportion in TP and FN (less in TP because they 
receive effective treatment).  
• All patients correctly identified as having the condition (TP) will be treated with 
cryotherapy that has proven useful in reducing development of cervical cancer and 
hence mortality from it.  
• All patients mislabeled as not having the disease (FN) will not be treated. 30% of 
them will naturally regress and no longer have CIN2/3 and 70% of them will persist 
to have CIN 2/3. 
• The FN group is the biggest contributor to mortality. 
• A higher value of sensitivity, will maximize the number of the patients in the TP 
group and decrease the number in the FN group and will decrease the number of 
patients whom will not receive treatment. 
• Specificity does not affect the numbers of patients who will die from cervical cancer. 
 
From our simple modeling HPV Vs VIA test on mortality outcomes, we concluded that for each one 
point increase the sensitivity for HPV or VIA, mortality (deaths) will decrease by 2 to 3 per million in a 
population with 2% prevalence of CIN. We also conclude that change in specificity in this example 
does not affect mortality and that is simply related to our assumption that mortality from cervical 
cancer happens in TP and FN.   
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Cervical cancer incidence CCI 
In our simple model, we assumed that cervical cancer is a consequence of having CIN which means 
that cervical cancer can happen in any patients who have CIN (TP and FN). However, cervical cancer 
will happen at a different rate in those who are treated (TP) and in those who are missed and not 
treated (FN). We also assumed that there will be no cervical cancer incidence in those who do not 
have CIN including both TN and FP. 
 
To calculate cervical cancer incidence in women with persistent CIN 2/3, we assumed 350 cervical 
cancers per 14000 women who have persistent CIN 2/3 (i.e. FN).  This incidence is based on Eastern 
Africa age standardized rate of cervical cancer of 350 cervical cancers per 1000000 women, of whom 
2% have CIN 2/3 (20000 women with CIN 2/3, and a subsequent 30% regression for a total of 14000 
with persistent CIN 2/3).   This data is available from WHO at http://globocan.iarc.fr/). 
Incidence of cervical cancer in woman with persistent CIN2/3 = 350/14000 = 0.025 
 
Our calculations in the model are based on 70% natural persistence of CIN 2/3 with no treatment 
(30% regression) in FN. 
  
(Persistence of CIN2/3 in FN group = (FN*0.7) 
Incidence of cervical cancer in FN= (FN*0.7)*0.025= FN *0.0175 
 
We assumed all TP are treated. Based on systematic reviews of treatment, we established that 
persistence/recurrence rates of CIN 2/3 are 5.3% in cryotherapy, and this was the value used in the 
model. 
If Incidence of cervical cancer in woman with persistent CIN2/3 = 350/14000 = 0.025 
 
Incidence of cervical cancer in TP group was (TP* 0.053)*0.025 = TP *0.001325 
 
In this example, the sensitivity of the test is a major determinant of the effect on cervical cancer 
incidence. This happens because: 
• The outcome evaluated (cervical cancer incidence), depend on progression of CIN 
2/3 in patients who have it whether treated (TP) or not (FN). 
• Incidence of cervical cancer occurs in a different proportion in TP and FN (less in TP 
because they receive effective treatment).  
• All patients correctly identified as having the condition (TP) will be treated with 
cryotherapy that has proven useful in reducing development of cervical cancer.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 26
• All patients mislabeled as not having the disease (FN) will not be treated. 30% of 
them will naturally regress and no longer have CIN2/3 and 70% of them will persist 
to have CIN 2/3. 
• The FN group is the biggest contributor to cervical cancer incidence because this 
group do not receive treatment. 
• A higher value of sensitivity, will maximize the number of the patients in the TP 
group and decrease the number in the FN group and will decrease the number of 
patients whom will not receive treatment. 
• Specificity does not affect the numbers of patients who will die from cervical cancer. 
 
From our simple modeling of HPV versus VIA test on cervical cancer incidence outcomes, we 
concluded that for each one point increase the sensitivity for HPV or VIA, new cases (incidence) will 
decrease by 3 per million in a population with 2% prevalence of CIN. We also conclude that change in 
specificity in this example does not affect incidence of cervical cancer and that is simply related to 
our assumption that cervical cancer incidence happens in TP and FN.   
 
Major bleeding 
In our simple model, we assumed that major bleeding is a complication of treatment which means 
that major bleeding can happen in any patients who receives treatment whether they have CIN or 
not that includes TP and FP. 
Based on systematic reviews of treatment, we established that 0.000339 of the population treated 
with cryotherapy will have major bleeding (1). 
 
In this example, the specificity of the test is a major determinant of the effect on major bleeding. This 
happens because: 
• The example assesses a relatively rare disease CIN2/3 with a low prevalence of 2% which 
means that only 2% of the patients will be TP and FN and 98% of the patients will be TN or FP 
• Major bleeding is a complication of treatment in patients identified as having CIN 2/3 (Test 
positive) 
• All patients identified as having the condition will be treated and suffer from complications 
whether they are correctly or incorrectly identified (TP or FP)  
The FP group is the main drive for the patients with major bleeding because due to the low 
prevalence, 98% of the patients will be TN or FP 
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• A higher value of specificity, will minimize the number of the patients with false positive test. 
On the other hand, a lower value of specificity, will increase the number of the patients with 
false positive test results which will impact the number of patients with major bleeding. 
 
In this example, using the simple model explained above, we found that with any sensitivity value 
above a minimum of 50% for HPV or VIA we can reduce 10 major bleeds with every 3% increase in 
the specificity. This trend is maintained regardless of the specificity value of the test and with 
sensitivity values equal to or greater than 50%. 
 
Premature delivery 
Premature delivery is a complication which occurs in pregnant women in a low proportion, however 
the risk is higher after a treatment with cryotherapy whether they have CIN or not, i.e. TP and FP.  
Based on systematic reviews of treatment, we established that 0.0005 of the general population will 
have premature delivery and 0.001125 of the population treated with cryotherapy will have 
premature delivery (1). 
 
In this example, the specificity of the test is a major determinant of the effect on premature delivery. 
This happens because: 
• The example assesses a relatively rare disease CIN2/3 with a low prevalence of 2% which 
means that only 2% of the patients will be TP and FN and 98% of the patients will be TN or FP 
• Premature delivery is a complication more frequent in patients identified as having CIN 2/3 
(Test positive) after the treatment 
• All patients identified as having the condition will be treated and suffer from complications 
whether they are correctly or incorrectly identified (TP or FP)  
• The FP group is the main drive for the patients with premature delivery because due to the 
low prevalence, 98% of the patients will be TN or FP 
• A higher value of specificity, will minimize the number of the patients with false positive test. 
On the other hand, a lower value of specificity, will increase the number of the patients with 
false positive test results which will impact the number of patients with major bleeding. 
 
In this example, using the simple model explained above, we found that with any sensitivity value 
above a minimum of 84% for HPV or VIA we can reduce 6 premature deliveries with every 1% 
increase in the specificity. This trend is maintained regardless of the specificity value of the test and 
with sensitivity values equal to or greater than 50%. 
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Major infections 
In our model, we assumed that major and minor infections are complications of treatment which 
means that major and minor infections can happen in any patients who receives treatment whether 
they have CIN or not, i.e. TP and FP. 
Based on systematic reviews of treatment, we established that 0.000135 of the population treated 
with cryotherapy will have major infection (1). 
 
In this example, the specificity of the test is a major determinant of the effect on major bleeding. This 
happens because: 
• The example assesses a relatively rare disease CIN2/3 with a low prevalence of 2% which 
means that only 2% of the patients will be TP and FN and 98% of the patients will be TN or FP 
• Major infection is a complication of treatment in patients identified as having CIN 2/3 (Test 
positive) 
• All patients identified as having the condition will be treated and suffer from complications 
whether they are correctly or incorrectly identified (TP or FP)  
The FP group is the main drive for the patients with major bleeding because due to the low 
prevalence, 98% of the patients will be TN or FP 
• A higher value of specificity, will minimize the number of the patients with false positive test. 
On the other hand, a lower value of specificity, will increase the number of the patients with 
false positive test results which will impact the number of patients with major infection. 
 
In this example, using the simple model explained above, we found that with any sensitivity value 
above a minimum of 50% for HPV or VIA we can reduce 13 major infections with every 10% increase 
in the specificity. This trend is maintained regardless of the specificity value of the test and with 
sensitivity values equal to or greater than 50%. 
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Methods – how the fully contextualized ranges were set in the example 
 
Table 1. Using estimated downstream health outcomes 
With the exemplified values, with an increase of 1% sensitivity we can accept a decrease with 4.5% in 
specificity (74.5/16.6 =4.5) 
Increase with 
1% sens 
Unit 
value 
Total value 
per outcome 
Increase with 1% 
spec 
Unit 
value 
Total value 
per outcome 
2.5 Deaths 20 50 6 Premature 
deliveries 
2 12 
3.5 Cervical 
cancers 
7 24.5 1.3 Major 
infections 
1 1.3 
   3.3 Major bleeds 1 3.3 
Total value  74.5   16.6 
 
Table 2. Using plausible shift in downstream health outcomes (increased risk of premature delivery 
in treated women 0.4% instead of the estimated 0.06%.) 
With the exemplified values, with an increase of 1% sensitivity we can accept a decrease with 0.8% in 
specificity (74.5/83 =0.9) 
Increase with 
1% sens 
Unit 
value 
Total value 
per outcome 
Increase with 
1% spec 
Unit 
value 
Total value per 
outcome 
2.5 Deaths 20 50 39.2 Premature 
deliveries 
2 78.4 
3.5 Cervical 
cancers 
7 24.5 1.3 Major 
infections 
1 1.3 
   3.3 Major 
bleeds 
1 3.3 
Total value  74.5   83.0 
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What is new? 
 
Key findings 
• This Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) concept paper shows that the choice of ranges is 
important when rating the certainty of evidence for test accuracy, since it 
may affect the interpretation of the result and the degree of certainty 
presented.   
• We present possible approaches for setting ranges for sensitivity and 
specificity for a single test and for a comparison of test options. The 
approaches are illustrated using an example of a direct comparison 
between two test strategies. 
 
What this adds to what was known? 
• The GRADE Working Group has previously clarified that the concept of 
certainty of evidence represents our confidence that the true effect lies 
above or below a threshold, or in a specified range. The frequent lack of 
direct evidence assessing the effect of medical tests on patient important 
outcomes highlights the need for a clarification of how these concepts 
apply to certainty ratings of test accuracy.  
What is the implication and what should change now? 
• When rating the certainty of evidence for test accuracy, it is important 
that systematic review authors, health technology assessors and 
guideline developers are transparent with the ranges they are using, the 
rational for choosing them as well as with the value judgments made.  
• More empirical data is needed before knowing which approaches, for 
defining ranges of accuracy, would be most useful for different purposes, 
and how to best operationalize them. 
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